Abstract: A pharmaceutical composition for treating or improving edema and blood stasis after open surgery according to an embodiment of the present disclosure includes an extract of a mixed herbal medicine including Prunus persica Batsch, Carthamus tinctorius Linmi, and Moutan Radicis Cortex as an active ingredient.

Abstract: The present disclosure relates to a composition for preventing, ameliorating or treating sleep disorder or insomnia, which contains an extract of a roasted citrus byproduct as an active ingredient. The extract of a roasted citrus byproduct of the present disclosure has very excellent effect of decreasing sleep latency, increasing sleep duration and increasing non-REM sleep. In addition, the composition of the present disclosure, which contains ingredients derived from the naturally occurring citrus byproduct, can ensure safety without inducing the side effects of synthetic drugs including pentobarbital and benzodiazepine and with no side effects such as cognitive impairment, tolerance or dependency even after long-term use. Accordingly, the composition for preventing, alleviating or treating sleep disorder, which contains an extract of a roasted citrus byproduct as an active ingredient, of the present disclosure is very useful for preparation of a food composition and a pharmaceutical composition.

Abstract: This disclosure relates to skin healthy compositions and methods of use thereof.

Abstract: Disclosed herein is a method for preparing a ginger extract from ginger rhizome. In certain embodiments, the method includes subjecting the ginger rhizome to a supercritical CO2 extraction to produce a gingerol fraction and an unextracted fraction; then extracting the unextracted fraction through refluxing ethanol extraction to produce an ethanol extracted fraction and unextracted fiber fraction; then fermenting the unextracted fiber fraction with yeast to produce fermented fibers; and finally combining the gingerol fraction the ethanol extracted fraction, fermented fiber fraction and gum Arabic and homogenizing to form a ginger extract homogenate and spry drying the ginger extract homogenate to produce a ginger extract powder. fermentation with yeast, combining the extracts, and homogenizing with gum arabic, and spray drying to form a ginger extract powder.

Abstract: The present invention relates to a peptide of length equal to or less than 5 amino acids, or a derivative thereof, comprising the sequence DKY, preferably XDKY (SEQ ID No. 7) or DKYX (SEQ ID No. 8), or the sequence DRY, preferably XDRY (SEQ ID No. 9) or DRYX (SEQ ID No. 10), where X is any amino acid, for use as a drug, particularly for use in the treatment of a disorder resulting from pathological angiogenesis, and a pharmaceutical composition comprising it together with at least one pharmaceutically acceptable excipient.

Abstract: The present invention relates to methods of treating or preventing alcohol dependence, enhancing the treatment of alcohol dependence, treating alcohol withdrawal, reducing alcohol consumption, alleviating one or more alcohol withdrawal symptoms in a subject, preventing or reducing the likelihood of alcohol dependence relapse in a subject treated for alcohol dependence, preventing alcohol-related N-methyl-D-aspartate receptor (NMDA) upregulation, preventing alcohol-related NMDA receptor activity, comprising administering a therapeutically effective amount of an NMDA receptor partial agonist (e.g., rapastinel) to the subject. The present invention further relates to compositions comprising an NMDA receptor partial agonist (e.g., rapastinel) for use with the aforementioned methods.

Abstract: Peptide compositions and their use for inhibiting tumor necrosis factor, pro-inflammatory cytokines and other inflammatory response mediators.

Abstract: The present invention provides a pharmaceutical composition for preventing or treating interstitial cystitis/bladder pain syndrome, the pharmaceutical composition containing an inhibitor against at least one type of integrin selected from the group consisting of integrin ?v?3, integrin ?v?5, and integrin ?5?1. The present invention also provides a method for evaluating the effect of a substance being tested on interstitial cystitis/bladder pain syndrome, the method including using, as an index, inhibiting activity against at least one type of integrin selected from the group consisting of ?v?3, ?v?5, and ?5?1.

Abstract: The KAI1 protein or a fragment thereof according to the present invention inhibited hepatic fibrosis in mice in which acute hepatic fibrosis was induced by CCl4. The KAI1 protein suppressed hepatic fibrosis by inhibiting fibrosis of hepatocytes treated with TGF-?1 and promoting senescence of hepatic stellate cells. Therefore, the pharmaceutical composition comprising the KAI1 protein according to the present invention may be used to effectively prevent or treat hepatic fibrosis.

Abstract: Provided herein are methods and compositions for treating a tumor or increasing the anti-cancer effectiveness of an immune checkpoint inhibitor using glycopeptide containing compositions.

Abstract: The present invention provides an isolated glucoregulatory compound having both insulinotropic and blood glucose lowering activities, a composition and uses thereof for treating diseases associated with insulin deficiency or failure in glucose uptake independent of insulin secretion by pancreatic cells such as hyperglycemia, type 1 diabetes, or type 2 diabetes mellitus in a subject.

Abstract: This disclosure relates to compositions and methods for recruiting brown adipocytes in vitro and in vivo from brown adipocyte progenitor cells found in human skeletal muscle. Methods for treating metabolic disease are also provided. Additionally, methods for treating hypothermia are provided. In some embodiments, the brown adipocyte recruiter is a human protein or peptide. In other embodiments the brown adipocyte recruiter may be a non-human protein or peptide. In still other embodiments, the brown adipocyte recruiter is a small molecule or natural product.

Abstract: This document provides methods and materials involved in promoting immune surveillance against cancer cells. For example, methods and materials administering one or more chemokine (C-X-C motif) ligand 14 (CXCL 14) polypeptides (and/or nucleic acids designed to encode a CXCL 14 polypeptide) to cancer cells within a mammal (e.g., a human) having cancer to promote immune surveillance against the cancer cells are provided.

Abstract: A method of treating a muscular dystrophinopathy, or a condition associated therewith, in a subject by administering to the subject a therapeutically effective amount of a composition comprising ALY688. The muscular dystrophinopathy can be Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), among others.

Abstract: Sublingual Semaglutide compositions may comprise both Semaglutide or a salt thereof and a gastric peptide or salt thereof, in combination. The use of a gastric peptide mitigates gastrointestinal side effects of Semaglutide. A weight loss regimen comprises administration of sublingual Semaglutide compositions in the physical form of sublingual tablets. In preferred embodiments, each sublingual Semaglutide tablet provides about 500 mcg Semaglutide or 750 mcg Semaglutide in combination with 300 mcg of gastric peptide, with the gastric peptide preferably comprising Body Protection Compound-157 (BPC-157). Sublingual administration of Semaglutide finds use in suppressing appetite, losing weight, and maintaining a desired personal appearance.

Abstract: A glucose-sensitive insulin-loaded microparticle which has a polymeric porous matrix made of a biocompatible and biodegradable polymer, insulin granules encapsulated within the polymeric porous matrix, and a blood glucose sensor attached to a surface of the glucose-sensitive insulin-loaded microparticle is provided. Use of the glucose-sensitive insulin-loaded microparticle for treatment of diabetes and for controlling glucose levels in the blood of a subject is also provided.

Abstract: The present invention relates to a long-acting PTH compound for use in the reduction of bone mineral density (BMD) in a patient having an increased BMD and to a particular dosage regimen of such long-acting PTH compound and other related aspects.

Abstract: Featured are pharmaceutical compositions that include a soluble alkaline phosphatase for treating bone mineralization disorders, such as hypophosphatasia (HPP), and symptoms thereof. The polypeptides include a soluble alkaline phosphatase (sALP) or fragment thereof, which is derived from a naturally occurring alkaline phosphatase (ALP).

Abstract: Novel fungal enzyme compositions, and more particularly, enzyme mixtures comprising a plurality of fungal enzymes (e.g., from Aspergillus and Candida) are provided. The disclosure further relates to dietary supplements, foods and beverages containing these enzyme mixtures, and methods of making and using the same.

Abstract: Disclosed is a hydrogel comprising a hydrophilic gelling agent that includes a nonionic cellulose ether, and active thermolysin, wherein the proteolytic activity of the thermolysin does not decrease by more than 20% when stored at room temperature for 6 months.

Abstract: This invention relates to botulinum toxin formulations that are stabilized without the use of any proteinaceous excipients. The invention also relates to methods of preparing and using such botulinum toxin formulations.

Abstract: The present disclosure arises at least in part from the seminal recognition that a combination treatment regimen including one or more cycles and/or doses of a checkpoint inhibitor and a therapeutic, either sequentially, in either order, or substantially simultaneously, can be more effective in treating cancer in some subjects and/or can initiate, enable, increase, enhance or prolong the activity and/or number of immune cells, or a medically beneficial response by a tumor.

Abstract: The present disclosure is directed to parasites that cause malaria, particularly Plasmodium-species parasites, and more particularly to Plasmodium-species parasites that have been genetically altered to develop normally only to the late liver stage but are completely inhibited in transition to blood stage or infection of erythrocytes. In particular, the inventors have identified genetic alterations that cause these parasites to arrest at the late liver stage of development, resulting from the disruption of the gene function of the liver stage nuclear protein (LINUP) gene. This complete late liver stage arrest allows for expression of an enhanced array of parasitic antigens throughout liver stage development, but prevents entry to blood stage, erythrocytic infection and the associated signs, symptoms and pathology of malaria disease.

Abstract: Compositions and methods for administering an active ingredient to an animal are disclosed. The compositions comprise powder compositions that can be used to prepare gel compositions comprising active ingredients as well as gel compositions comprising the active ingredients. Methods of preparing the gel compositions and methods of administering the active ingredient to the animal are also disclosed.

Abstract: The present invention refers to a freeze-dried composition consisting of an isolated microorganism belonging to the Mycobacterium tuberucolosis complex, preferably a M. tuberculos clinical isolate, more preferably M. tuberculosis clinical isolate, characterized in that it comprises a PhoP? phenotype by the inactivation by a genetic deletion of the Rv0757 gene and the deletion of a second gene, Rv2930 (fadD26), that prevents PDIM production (PDIM? phenotype) (the MTBVAC strain), and sucrose and sodium glutamate as stabilizers or excipients. The present invention further refers to the reconstituted composition obtained by adding water, preferably sterilized water for injection, to the freeze-dried composition as well as uses thereof, in particular for use as a prophylactic agent to those at risk of infection with M. tuberulosis or those at risk of developing tuberculosis disease, or as secondary agents for treating infected tuberculosis patients.

Abstract: The invention is related to multivalent immunogenic compositions comprising more than one S. pneumoniae polysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from an S. pneumoniae serotype conjugated to a carrier protein, wherein the serotypes of S. pneumoniae are as defined herein. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection against S. pneumoniae infection and/or pneumococcal diseases caused by S. pneumoniae. The compositions of the invention are also useful as part of treatment regimes that provide complementary protection for patients that have been vaccinated with a multivalent vaccine indicated for the prevention of pneumococcal disease.

Abstract: Disclosed are methods of preparing an isolated population of human papillomavirus (HPV)-specific T cells comprise dividing an HPV-positive tumor sample into multiple fragments; separately culturing the multiple fragments; obtaining T cells from the cultured multiple fragments; testing the T cells for specific autologous HPV-positive tumor recognition; selecting the T cells that exhibit specific autologous HPV-positive tumor recognition; and expanding the number of selected T cells to produce a population of HPV-specific T cells for adoptive cell therapy. Related methods of treating or preventing cancer using the T cells are also disclosed.

Abstract: In alternative embodiments, provided are methods for treating, ameliorating, decreasing the chances of having any adverse effects from, decreasing the severity of adverse effects from a coronavirus infection, comprising administering to a subject or an individual in need thereof: (a) an anti-viral drug combination capable of killing a causative agent of the infection, or completely or partially inhibiting the ability of the causative agent of the infection to replicate or become infectious or cause pathology in the subject or the individual in need thereof, wherein the anti-viral drug combination comprises: (i) 1R,2S,5S)—N-[(1S)-1-cyano-2-[(3S)-2-oxopyrrolidin-3-yl]ethyl]-3-[(2S)-3,3-dimethyl-2-(2,2,2-trifluoroacetamido)butanoyl]-6,6-dimethyl-3-azabicyclo[3.1.

Abstract: The invention concerns a method of producing a foot and mouth disease virus (FMDV) virus-like particle (VLP) in a baculovirus expression system, the method comprising the steps of (i) infecting an insect cell with a baculovirus expression vector, (ii) culturing the insect cell in cell culture medium for 4 days or more post infection, (iii) separating the insect cells from the cell culture to obtain cell-free cell culture medium, and (iv) harvesting the FMDV VLP from the cell-free cell culture medium. The invention further relates to a vaccine for use in the protection of a subject against an infection with FMDV, the vaccine being obtainable by the method of the invention.

Abstract: The present disclosure is directed to Compositions comprising a population of multivalent viral particles are described herein. Also described herein are immunogenic compositions comprising a population of multivalent viral particles. Additionally, methods of making a multivalent immunogenic composition comprising a population of multivalent viral particles are described. Lastly, methods of using an immunogenic composition to elicit an immune response in a subject are described herein.

Abstract: The disclosure relates to pan human coronavirus ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines.

Abstract: The present invention relates to nanovesicles which express immunomodulatory proteins or targeting proteins, methods for preparing the same and uses thereof. More specifically, the present invention provides plasma membrane bleb-based nanovesicles which are prepared more homogeneously than existing plasma membrane bleb-based nanovesicles, by using cell lines expressing various immunomodulatory proteins or targeting proteins in the plasma membrane as materials, methods for preparing the nanovesicles, pharmaceutical compositions including the nanovesicles, methods for inducing immunity using the nanovesicles and methods for signal transduction or targeting using the nanovesicles.

Abstract: The present invention relates to immunogenic compositions and combinations thereof which may find use in immunisation regimens for the treatment of chronic hepatitis B. An immunogenic composition comprises a replication-defective chimpanzee adenoviral (ChAd) vector comprising polynucleotides encoding HBs, HBc human invariant chain (hIi) fused to the HBc. Another immunogenic composition comprises a Modified Vaccinia Virus Ankara (MVA) vector comprising polynucleotides encoding HBs and HBc. Another immunogenic composition comprises recombinant HBs, C-terminal truncated recombinant HBc and an adjuvant containing MPL and QS-21.

Abstract: A Hepatitis B virus (HBV) vaccine comprising a fusion protein of a preS polypeptide fused to at least one grass pollen allergen peptide, for use in the treatment of a subject to induce HBV neutralizing antibodies, wherein the subject is an immune tolerant human subject and said treatment comprises repeated vaccination to break immune tolerance against HBV.

Abstract: This invention relates to the use of S. pneumoniae protein antigens, such as NanA, PluA and Sp0148, as carriers for immunogenic S. pneumoniae capsular polysaccharide. This may be useful for example in glycoconjugate vaccines able to generate a protective immune response against multiple capsuler serotypes. Glycoconjugates, vaccine compositions and methods of manufacture and use are provided.

Abstract: The present invention relates to antibodies against SARS-CoV-2 and uses thereof in the medical field for the prevention and treatment of SARS-CoV-2 infection and COVID-19 disease.

Abstract: Disclosed herein are compositions comprising engineered antigen-specific Tregs that suppress antibody formation against the soluble therapeutic protein factor VIII in an MIC-independent fashion. Complexing TCR-based signaling with single-chain variable fragment (scFv) recognition to generate TCR fusion construct (TRUC)-Tregs delivered controlled antigen-specific signaling via engagement of the entire TCR complex, thereby directing functional suppression of the FVIII-specific antibody response.

Abstract: The present invention relates to methods and compositions for treating autoimmune or inflammatory disease characterised by an aberrant or inappropriate immune response to one or more of Ro60 protein; MPO protein; and Smith protein.

Abstract: Methods for inducing plasticity in effector T cells or intermediate Treg cells to exhibit a regulatory T cell phenotype, treating an autoimmune disease, enriching Treg cells, and preparing a subject for an organ transplant are described. The methods involve the simultaneous/synergistic inhibition of eIFSA and Notch signaling. Also described are compositions and kits including an eIPSA inhibitor and a Notch signaling inhibitor.

Abstract: Cancer stem cells (CSCs) are a subpopulation of tumor cells that can drive tumor initiation and can cause relapses. These cells are seen as drivers of tumor establishment and growth, often correlated to aggressive, heterogeneous and therapy-resistant tumors. Novel tumor-specific antigens (TSAs) and tumor-associated antigens (TAAs) specifically expressed by CSCs are described herein. Most of the TSAs described herein derives from aberrantly expressed unmutated genomic sequences, such as intronic and intergenic sequences, which are not expressed in normal tissues. Nucleic acids, compositions, cells, antibodies and vaccines derived from these TSAs are described. The use of the TSAs, nucleic acids, compositions, antibodies, cells and vaccines for the treatment of cancer, and more particularly cancers associated with the presence of CSCs such as poorly differentiated cancers, is also described.

Abstract: The current disclosure provides for techniques and approaches for the generation of autologous mutant neoantigen-specific, TCR-engineered T cells used for adoptive transfer in treatment of cancer patients. Also provided are surrogate cancer cells, which is a personalized cell system that can be used for vaccination and TCR discovery in cancer patients.

Abstract: Anaplastic large cell lymphoma (ALCL) is a rare and aggressive peripheral T-cell lymphoma affects lymph nodes and extra-nodal sites with characteristic skin lesions. Approximatively half of the tumors express the NPM1-ALK fusion from the translocation t(2;5)(p23;q32). In the present study, the inventors identify ROR2 as progressively up regulated thought tumorigenesis. Patient samples show a significantly high ROR2 expression (transcriptomic data) as well as a strong ROR2 protein expression (IHC) with some tumors displaying a clear membrane signal. ROR2 mRNA expression level is also positively correlated to NPM-ALK expression level in tumor cells and is not expressed in normal T cells. In addition, ROR2 protein level is significantly increased in resistant cells to the ALK inhibitor, crizotinib, used in clinical trials for children with refractory tumors.

Abstract: Aspects of the present disclosure are directed to immune cells comprising polynucleotides encoding genetically engineered receptors (e.g., chimeric antigen receptors, T-cell receptors) and having anti-CD20 antibodies (or fragments thereof) attached to their surface. Certain aspects are directed to preactivated and/or expanded natural killer cells having anti-CD20 antibodies (or fragments thereof) attached to their surface. Also disclosed are compositions comprising such cells, and methods for using such compositions to treat an individual having CD20-positive cancer. Further aspects encompass methods for cell preparation comprising culturing natural killer cells with cytokines (e.g., IL-12, IL-15, and/or IL-18) and incubating the cells with an anti-CD20 antibody.

Abstract: Some embodiments provide a system for external manipulation of magnetic nanoparticles in vasculature using a remotely placed magnetic field-generating stator. In one aspect, the systems and methods relate to the control of magnetic nanoparticles in a fluid medium using permanent magnet-based or electromagnetic field-generating stator sources. Such a system can be useful for increasing the diffusion of therapeutic agents in a fluid medium, such as a human circulatory system, which can result in substantial clearance of fluid obstructions, such as vascular occlusions, in a circulatory system resulting in increased blood flow.

Abstract: A method for controlling ultrasonic waves to induced sonoporation of a drug into cancer cells in a tumor. The method may include accessing configuration data that may include a type of the tumor and a type of drug, and determining values of operational parameters that may be based on the configuration data to define determined values. The operational parameters may include frequency value and duty cycle value. The method may also include determining frequency value which may be based on the type of tumor that may define a determined frequency value, and determining the duty cycle value which may be based on the type of drug and the type of tumor that may define a determined duty cycle value.

Abstract: The present invention relates to the technical field of medicine, and in particular, relates to a composition of vancomycin aqueous solution. The pharmaceutical composition contains vancomycin or a pharmaceutically acceptable salt thereof, N-methylalanine, and water. The stability of vancomycin in the state of an aqueous solution can be improved by using N-methylalanine.

Abstract: Pharmaceutical formulations comprising anti-inflammatory and/or pain-reducing agents that are insoluble or have low solubility in water are formulated with a solubility enhancer such as MSM to increase solubility. The enhanced solubility of the agents in the presence of MSM allows use of reduced amounts of drugs and thus significantly increases efficiency and reduces harmful side-effects associated with these agents.

Abstract: The invention relates to mixtures comprising one or more phospholipids, wherein at least 2 wt % of the phospholipids bears a net negative charge, and/or is deprotonable, whereby the mixture comprises a weak basic salt; one or more oils, butters and/or triglycerides; one or more lipophilic or poorly water-soluble biologically active ingredients; and one or more liquid or solid polyols, sugars, monohydric and/or poly hydric alcohols. The invention further relates to sealed and air- or oxygen-impermeable and liquid-im-permeable containers comprising such mixture and the preparation thereof.

Abstract: The present invention relates to bifunctional compounds, which find utility to degrade and (inhibit) TBK1. In particular, the present invention is directed to compounds, which contain on one end an E3 ubiquitin ligase binding moiety which binds to an E3 ubiquitin ligase and on the other end a moiety which binds TBK1 such that TBK1 is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of TBK1. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of TBK1.

Abstract: The present disclosure relates to a conjugate comprising a YAP/TAZ-TEAD Protein Protein Interaction Inhibitor (PPII) linked to a Ligase Binder via a linker, or a pharmaceutically acceptable salt thereof, as well as methods of using such conjugates.